System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Massimo Puoti is an expert in Hepatology at Ospedale Niguarda Ca' Granda (Italy). As of October 2026, ScienceLeadR ranks Massimo Puoti in the top 1% of experts worldwide for Hepatitis. Massimo Puoti has authored 667 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 4 of them ongoing. SLR score: 2,032 (community average: 125). How the SLR is computed.

LeadR Profile

Massimo Puoti Ospedale Niguarda Ca' Granda Italy
2 032 ScienceLeadR Reputation 2032

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1988 - 2026
Source: PubMed

Ospedale Niguarda Ca' Granda

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 667

Citations

Citations: 29 351 1st author: 53 Last author: 72 Unique author: 1

Main journals

J Hepatol 114
Dig Liver Dis 91
J Antimicrob Chemother 27
AIDS 24
Clin Infect Dis 22

Best Journals

J Hepatol 16
N Engl J Med 5
Lancet 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Trends in Hepatitis D Virus Prevalence Among HBsAg-Positive Individuals With and Without HIV in Italy: A Converging Epidemiology.
PMID 42834655 — hepatitis b surface antigens, hepatitis d, epidemiology, pharmaceutical preparations, hepatitis delta virus, liver, viruses, prevalence, infections, hepatitis		Liver Int20260
Persistent ALT Elevation and Liver Outcomes After DAA-Induced HCV Cure in People With HIV: Impact of HBV and HDV Co-Infections.
PMID 42764626 — research design, coinfection, liver, therapeutics, hepatitis, viral, human, antiviral agents, infections, hepatitis		J Viral Hepat20260
Direct-Acting Antivirals in Patients with Comorbidities for the Simplified Management of HCV Infection: An Expert Review with a Focus on Sofosbuvir-Velpatasvir.
PMID 42655672 — comorbidity, polypharmacy, pharmaceutical preparations, virology, sofosbuvir, therapeutics, antiviral agents, infections		Viruses20261
Obesity at antiretroviral therapy initiation and long-term risk of cardiovascular disease, cancer, or death in people with HIV in Italy: a prospective cohort study.
PMID 42633417 — cardiovascular diseases, neoplasms, cohort studies, aged, obesity, therapeutics		EClinicalMedicine20260
Additional considerations regarding the antibiotic treatment for Mycoplasma genitalium infection.
PMID 42625523 — therapeutics, mycoplasma, communicable diseases, mycoplasma genitalium, infections		Clin Infect Dis20260

Clinical Studies 18

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 11
N/A 3
Phase 2 2
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 11
Active not recruiting 3
Recruiting 2
Unknown 2

By type:

Interventional 16
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 17

Main Topics

Cohort/Consortium Investigators 52

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Global Randomized Open label Multicenter Phase 3 Trial Evaluating BJT 778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE 2)
2024-517167-23-00 — hepatitis d, hepatitis d, chronic, hepatitis, chronic, therapeutics, infections, hepatitis		Phase 3Recruiting2025
Phase 2b 3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
2025-522015-42-00 — hepatitis d, safety, hepatitis d, chronic, hepatitis, chronic, therapeutics, infections, hepatitis		Phase 2/Phase 3Recruiting2026
Early DOlutegravir LAmivudine Switching after virological suppression (EDOLAS Study)
2024-518909-18-00 — hiv-1, safety, pharmaceutical preparations, lamivudine, hiv, rna, dolutegravir		Phase 3Active not recruiting2021
A Multicenter Randomized Double Blind Placebo controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Participants living with Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment
2023-509588-25-00 — safety, hepatitis b virus, herpesviridae infections, hepatitis, chronic, herpesvirus 1, cercopithecine, hiv, viruses, therapeutics, hepatitis b, hepatitis b, chronic, infections, hepatitis, virus diseases		Phase 2Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS